Is high-dose beta-lactam therapy associated with excessive drug toxicity in critically ill patients?

Mcdonald, Craig, Cotta, Menino O., Little, Peter J., Mcwhinney, Brett, Ungerer, Jacobus P. J., Lipman, Jeffrey and Roberts, Jason A. (2016) Is high-dose beta-lactam therapy associated with excessive drug toxicity in critically ill patients?. Minerva Anestesiologica, 82 9: 957-965.

Author Mcdonald, Craig
Cotta, Menino O.
Little, Peter J.
Mcwhinney, Brett
Ungerer, Jacobus P. J.
Lipman, Jeffrey
Roberts, Jason A.
Title Is high-dose beta-lactam therapy associated with excessive drug toxicity in critically ill patients?
Journal name Minerva Anestesiologica   Check publisher's open access policy
ISSN 0375-9393
1827-1596
Publication date 2016-09-01
Sub-type Article (original research)
Open Access Status Not yet assessed
Volume 82
Issue 9
Start page 957
End page 965
Total pages 9
Place of publication Turin, Italy
Publisher Edizioni Minerva Medica
Collection year 2017
Language eng
Formatted abstract
Background: β-lactam antibiotics may necessitate higher than licensed drug doses to achieve therapeutic exposures in critically ill patients. Therapeutic drug monitoring can be used to guide dosing so as to maximise therapeutic effect whilst reducing the likelihood of exposure-related toxicity.

Methods: A retrospective review of critically ill patients identified those that received higher than licensed doses of either meropenem (3-6 g/day) or piperacillin-tazobactam (16 g-2 g/day) (i.e. high-dose group) guided by therapeutic drug monitoring. β-lactam-associated toxicities were compared with a patient group of similar age, sex, body mass index and admission diagnosis that received licensed doses of either antibiotic.

Results: Mean daily doses were more than 40% higher in the high-dose groups for each antibiotic. There were no significant differences between the high-dose and licensed-dose groups in terms of hepatocellular derangement (17.9% vs. 31.8%, P=0.25 for meropenem and 17.4% vs. 16.0%, P=0.90 for piperacillin-tazobactam), cholestasis (28.0% vs. 13.6%, P=0.32 for meropenem and 13.0% vs. 4.0%, P=0.26 for piperacillin-tazobactam), need for continuous renal replacement therapy (0% vs. 9.1%, P=0.10 for meropenem and 0% vs. 8.0%, P=0.16 for piperacillin-tazobactam), seizure incidence (7.1% vs. 4.5%, P=0.70 for meropenem and nil for either piperacillin-tazobactam group), thrombocytopenia (9.1% vs. 10.7%, P=0.85 for meropenem and 4.0% vs. 4.3% for piperacillin-tazobactam), or neutropenia (4.5% vs. 3.6%, P=0.95 for meropenem and 0.0% vs. 4.3% for piperacillin-tazobactam).

Conclusions: Higher than licensed doses of meropenem and piperacillin-tazobactam guided by therapeutic drug monitoring were not associated with additional toxicities. Larger prospective studies are required to confirm the clinical utility of higher than licensed dosing.
Keyword Beta-lactams
Drug monitoring
Toxicity
Critical illness
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 27 Nov 2016, 10:19:46 EST by System User on behalf of Learning and Research Services (UQ Library)